Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Triplet Therapy With Navitoclax, Venetoclax, and Decitabine for High-risk Myeloid Malignancies

NCT05455294 is registered in ClinicalTrials.gov with Jacqueline Garcia, MD as lead sponsor.

NCT NCT05455294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05455294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Triplet Therapy With Navitoclax, Venetoclax, and Decitabine for High-risk Myeloid Malignancies
Lead sponsor
Jacqueline Garcia, MD
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 18, 2022
Completion date
December 31, 2026
Enrollment
16 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, myelodysplastic syndromes, myelofibrosis, myeloid malignancy, myeloproliferative neoplasm